Bryostatin 1 activates T cells that have antitumor activity

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Tumor-specific T cell expansion is crucial for effective cancer immunotherapy.
• Pharmacologic agents can activate T-cell signaling pathways to enhance immune responses.

Purpose of the Study:

• To investigate the efficacy of bryostatin 1 (a protein kinase C activator) and ionomycin (a calcium ionophore) in stimulating tumor-specific T cells.
• To assess the in vitro proliferation, expansion, and cytotoxic activity of lymphocytes treated with bryostatin 1 and ionomycin.
• To evaluate the in vivo anti-tumor effects of T cells expanded using this method.

Main Methods:

• Lymphocytes from tumor-draining lymph nodes were co-cultured with autologous tumor cells and IL-2.
• Cells were subsequently restimulated with varying concentrations of bryostatin 1 and ionomycin.
• Proliferation, cell expansion, T cell phenotype (CD8+), and in vitro cytotoxicity were assessed.
• Adoptive transfer of expanded T cells into tumor-bearing mice was performed to evaluate in vivo efficacy.

Main Results:

• Bryostatin 1 plus ionomycin significantly enhanced lymphocyte proliferation and cell numbers (15-fold expansion over 2 weeks).
• The expanded T cells were predominantly CD8+ and maintained specific cytotoxicity against autologous tumor cells.
• Adoptive transfer of these T cells led to specific tumor regression in mice with liver metastases.

Conclusions:

• The combination of bryostatin 1 and ionomycin is a potent method for expanding tumor-specific T cells.
• This approach generates cytotoxic CD8+ T cells capable of mediating significant anti-tumor effects in vivo.
• This strategy holds promise for developing novel cancer immunotherapies.